I obatained my Ph.D. in Cell Biology and Pathology from Universtiy of Barcelona in 2008 and in 2009 I joined the laboratory of Dr. Abate-Shen as a postdoctoral fellow at Columbia University (New York) working on developing genetically-engineered mouse models and computational approaches to uncover acctionable driver mechanisms in prostate cancer. In 2015 I was recruited as faculty at the joint initiative from IDIBELL and the Catalan Institute of Oncology to launch the Program Against Cancer Therapeutic Resistance.

Lab members

Katia RuggeroPostdoctoral Research ScientistPh.D. University of Padua, Italy

I obtained my Ph.D in 2012 at the University of Padua, where I studied the role of microRNAs in oncogenic transformation driven by human T-cell leukemia virus type 1. In 2013 I join the laboratory of Prof. Rabbitts as a postdoctoral fellow at the WIMM in Oxford, workning on mechanisms of oncogenesis in LMO2-directed T cell leukaemia. In 2016 I joined Dr. Aytes laboratory to carry out reaserch on the role of epigenetic mechanisms of therapeutic resistance in prostate cancer.

Sonia´s Master´s thesis focuses on dissecting the cell cycle independent functions of the master regulators FOXM1 and CENPF, with a particular interest in epigentically controlled oncogen activation. While she continues that line of research she is also focusing on the role PARPi in HDR proficient prostate cancer tumors.

Adrian perfomed his Master´s thesis in the Vall d'Hbron Research Institute (VHIR). In our lab he is developing tools and assays for CRISPR/cas9-based genome wide and targeted screenings for synthetic lethal interactions and mecghanisms of resistance to AR targeting agents such as Abiraterone or other novel anti-AR.

Sonia´s Master´s thesis focuses on dissecting the cell cycle independent functions of the master regulators FOXM1 and CENPF, with a particular interest in epigentically controlled oncogen activation. While she continues that line of research she is also focusing on the role PARPi in HDR proficient prostate cancer tumors.